about
The Efficacy and Safety of the Combination of Total Glucosides of Peony and Leflunomide for the Treatment of Rheumatoid Arthritis: A Systemic Review and Meta-AnalysisMetabolomics in rheumatic diseases: desperately seeking biomarkersCurrent status of lupus nephritis.Etanercept-induced pityriasis lichenoides chronica in a patient with rheumatoid arthritis.Current and future trends in biomarker discovery and development of companion diagnostics for arthritis.Synergistic anti-tumour effects of tetrandrine and chloroquine combination therapy in human cancer: a potential antagonistic role for p21.Expression and pathological effects of periostin in human osteoarthritis cartilageChondrocyte Apoptosis in Rheumatoid Arthritis: Is Preventive Therapy Possible?Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug InteractionsmiR-573 is a negative regulator in the pathogenesis of rheumatoid arthritis.Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort StudyProtein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives.Treatment of severe lupus nephritis: the new horizon.Nanodiagnostics, nanopharmacology and nanotoxicology of platelet-vessel wall interactions.Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events.Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics.Combination Therapy of PEG-HM-3 and Methotrexate Retards Adjuvant-Induced Arthritis.MetabolitePredict: A de novo human metabolomics prediction system and its applications in rheumatoid arthritis.Management of rheumatoid arthritis: Impact and risks of various therapeutic approachesRegulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions.Design, synthesis and evaluation of ()-3-(7-(methyl(7-pyrrolo[2,3-]pyrimidin-4-yl)amino)-5-azaspiro[2.4]heptan-5-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor‘Bamboo spine’, a thing of the past?
P2860
Q26752893-374EA8D6-F8E6-4595-8049-AD04EF7C7231Q26765005-D521B871-1C27-4652-B6D3-FFBD5D82FDCDQ33882751-F7ABA6DB-5AB0-46D7-831E-99C2D30E2970Q35144172-DC7349BF-0060-43DB-8431-12D77F18F9BFQ35470652-2C410BE2-CD59-4AE9-B869-72647530ABD3Q35484306-34855DF6-7859-4FCB-ADC8-5F471502ACE8Q35750612-EF19A1B5-BD1D-42F6-8494-9B7793502C41Q36574607-0C1AA2FA-D53B-4677-AC39-DA99439A4DEFQ37145705-DAF92260-41A3-444F-97A1-A691565AD3D6Q37402448-6C601DF4-5127-41FD-BBA6-48F897F8CB93Q37452967-FF703F23-93C9-43B5-B906-D27C346CD09FQ38251801-58EC1A46-6143-4618-BF3A-990647181423Q38271125-B2819597-4E99-4D5C-B26F-892CBB249B13Q38495085-874455F4-93EC-4B94-85FA-A9AB62DF857DQ38643965-4DFE040F-DB08-4706-969F-056AEE9145DEQ38645738-99D3E57A-C3AD-41D3-B907-064A4FDBB8D9Q38650245-0BA5708B-1EA4-4584-8ACA-8286D2B894A9Q38733350-1F3C9468-526F-48E8-81B2-425E634CAE1FQ39646028-E435FFC3-7C93-401A-95C9-38EE15989CCCQ55046512-DF3DE2A6-6ACE-4544-874A-46B2D64A5425Q57557905-9357DD05-9C0C-4B3C-9350-E4CDF1246648Q57673065-D980AA58-767C-4CE4-BD11-39DE5D8DE63A
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Current immunotherapy in rheumatoid arthritis.
@en
type
label
Current immunotherapy in rheumatoid arthritis.
@en
prefLabel
Current immunotherapy in rheumatoid arthritis.
@en
P2093
P2860
P356
P1433
P1476
Current immunotherapy in rheumatoid arthritis.
@en
P2093
Florian M P Meier
Marc Frerix
Walter Hermann
P2860
P304
P356
10.2217/IMT.13.94
P577
2013-09-01T00:00:00Z